Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme
NCT00800917Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Nov 2008
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in glioblastoma multiforme (GBM), sponsored by Rigshospitalet. Primary endpoint: Progression-free survival. Started Nov 2008; status: completed.
02
Drugs
temsirolimus
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00800917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00800917.